[go: up one dir, main page]

NO20090053L - Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer - Google Patents

Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Info

Publication number
NO20090053L
NO20090053L NO20090053A NO20090053A NO20090053L NO 20090053 L NO20090053 L NO 20090053L NO 20090053 A NO20090053 A NO 20090053A NO 20090053 A NO20090053 A NO 20090053A NO 20090053 L NO20090053 L NO 20090053L
Authority
NO
Norway
Prior art keywords
cancer
treatment
methods
tak1 inhibitors
tak1
Prior art date
Application number
NO20090053A
Other languages
English (en)
Norwegian (no)
Inventor
Kate Byth
Sangeetha Palakurthi
Lihua Yu
Qi Zhang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20090053L publication Critical patent/NO20090053L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO20090053A 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer NO20090053L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80684506P 2006-07-10 2006-07-10
PCT/GB2007/002568 WO2008007072A2 (fr) 2006-07-10 2007-07-10 Procédé d'inhibition cellulaire

Publications (1)

Publication Number Publication Date
NO20090053L true NO20090053L (no) 2009-02-06

Family

ID=38920633

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090053A NO20090053L (no) 2006-07-10 2009-01-06 Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer

Country Status (12)

Country Link
US (1) US20090312396A1 (fr)
EP (1) EP2041303A2 (fr)
JP (1) JP2009544583A (fr)
KR (1) KR20090027735A (fr)
CN (1) CN101490279A (fr)
AU (1) AU2007274055A1 (fr)
BR (1) BRPI0714158A2 (fr)
CA (1) CA2658163A1 (fr)
IL (1) IL196208A0 (fr)
MX (1) MX2009000376A (fr)
NO (1) NO20090053L (fr)
WO (1) WO2008007072A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101559B2 (en) * 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
GB0918579D0 (en) 2009-10-22 2009-12-09 Imp Innovations Ltd Gadd45beta targeting agents
CN101968491A (zh) * 2010-09-29 2011-02-09 上海生物芯片有限公司 弥漫性大b细胞淋巴瘤分子病理分型方法及试剂盒和应用
GB201107118D0 (en) * 2011-04-27 2011-06-08 Imp Innovations Ltd Method of diagnosis and prognosis
WO2012166722A1 (fr) * 2011-06-03 2012-12-06 The General Hospital Corporation Traitement du cancer colorectal, pancréatique et pulmonaire
WO2013012998A1 (fr) 2011-07-19 2013-01-24 Emory University Inhibiteurs de kinase tak1, compositions et utilisations associées
EP3079682A4 (fr) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Procédé pour traiter un lymphome lymphoplasmocytaire
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3715346B1 (fr) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Composés contenant des groupes thiazolyle pour le traitement de maladies prolifératives
CN104911183B (zh) * 2015-06-25 2018-01-09 中山大学孙逸仙纪念医院 抑制胰腺癌TAK1基因表达的shRNA的转录模板
WO2018060452A1 (fr) * 2016-09-30 2018-04-05 Fundació Institut Mar D'investigacions Mèdiques (Imim) Approches thérapeutiques contre le cancer
CN109420170B (zh) 2017-08-25 2021-03-02 中国科学院上海营养与健康研究所 肿瘤微环境相关靶点tak1及其在抑制肿瘤中的应用
EP4464318A1 (fr) * 2023-05-19 2024-11-20 Albert-Ludwigs-Universität Freiburg Ciblage de l'activation de la kinase 1 activée par tgf-b dans le traitement d'états neuro-inflammatoires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025362A1 (de) * 2004-05-19 2005-12-22 Sanofi-Aventis Deutschland Gmbh Verwendung der TGFbeta-aktivierten Kinase 1
WO2006023210A2 (fr) * 2004-07-23 2006-03-02 Aveo Pharmaceuticals, Inc. Gene gp132: techniques et compositions de traitement du cancer
WO2007044571A2 (fr) * 2005-10-06 2007-04-19 President And Fellows Of Harvard College Procedes permettant d'identifier des proteines essentielles a la proliferation des cellules humaines, et agents therapeutiques diriges contre ces proteines

Also Published As

Publication number Publication date
EP2041303A2 (fr) 2009-04-01
BRPI0714158A2 (pt) 2012-12-25
WO2008007072A8 (fr) 2009-02-26
CA2658163A1 (fr) 2008-01-17
KR20090027735A (ko) 2009-03-17
WO2008007072A3 (fr) 2008-05-08
CN101490279A (zh) 2009-07-22
MX2009000376A (es) 2009-03-09
WO2008007072A2 (fr) 2008-01-17
IL196208A0 (en) 2009-09-22
AU2007274055A1 (en) 2008-01-17
JP2009544583A (ja) 2009-12-17
US20090312396A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
NO20090053L (no) Metoder for behandling av cancer ved anvendelse av TAK1 inhibitorer
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
EP2331530B8 (fr) Composés multicycliques fusionnés en tant qu inhibiteurs des protéines kinases
MX2013004086A (es) Metodos para inhibir proliferacion celular en cancers accionados por egfr.
ES2583010T3 (es) Nuevos inhibidores de la ruta de Stat3 e inhibidores de células madre del cáncer
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
WO2009134658A3 (fr) Composés de pyrimidine bicycliques fusionnés en tant qu'inhibiteurs d'aurora kinase
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
IN2012DN03012A (fr)
MX2009006542A (es) Inhibidores de histona desacetilasa y sus profarmacos.
MX2011011735A (es) Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
MY147832A (en) Compounds for enzyme inhibition
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
NO20082683L (no) Neuroendokrin tumorbehandling
GEP20135957B (en) Heterocyclic compound and usage thereof
MX2010005395A (es) Metodo para tratar artritis.
WO2010042933A3 (fr) Inhibition et traitement des métastases du cancer de la prostate
TN2012000205A1 (en) Method and compositions for treating solid tumors and other malignancies
WO2006055635A3 (fr) Compositions et methodes de modification de la signalisation autocrine wnt
EA201101041A1 (ru) Производные пиридазинона

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application